1. |
國家衛生健康委. “十四五”全國眼健康規劃(2021-2025年)[EB/OL]. [2022-01-04]. http://www.nhc.gov.cn/yzygj/s7653/202201/d607d24b6b1c4bd9b827eedf41eff820.shtml.National Health Commission. 14th Five-Year Plan for Eye Health (2021-2025)[EB/OL]. [2022-01-04]. http://www.nhc.gov.cn/yzygj/s7653/202201/d607d24b6b1c4bd9b827eedf41eff820.shtml.
|
2. |
Song P, Du Y, Chan KY, et al. The national and subnational prevalence and burden of age-related macular degeneration in China[J/OL]. J Glob Health, 2017, 7(2): 20703[2017-12-01]. https://pubmed.ncbi.nlm.nih.gov/29302323/. DOI: 10.7189/jogh.07.020703.
|
3. |
Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis[J/OL]. Lancet Glob Health, 2014, 2(2): e106-e116[2014-01-03]. https://pubmed.ncbi.nlm.nih.gov/25104651/. DOI: 10.1016/S2214-109X(13)70145-1.
|
4. |
Ye H, Zhang Q, Liu X, et al. Prevalence of age-related macular degeneration in an elderly urban chinese population in China: the Jiangning eye study[J]. Invest Ophthalmol Vis Sci, 2014, 55(10): 6374-6380. DOI: 10.1167/iovs.14-14899.
|
5. |
Teo ZL, Tham YC, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis[J]. Ophthalmology, 2021, 128(11): 1580-1591. DOI: 10.1016/j.ophtha.2021.04.027.
|
6. |
Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy[J]. Diabetes Care, 2012, 35(3): 556-564. DOI: 10.2337/dc11-1909.
|
7. |
Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050[J]. Ophthalmology, 2016, 123(5): 1036-1042. DOI: 10.1016/j.ophtha.2016.01.006.
|
8. |
Baird PN, Saw SM, Lanca C, et al. Myopia[J]. Nat Rev Dis Primers, 2020, 6(1): 99. DOI: 10.1038/s41572-020-00231-4.
|
9. |
Scott IU, Campochiaro PA, Newman NJ, et al. Retinal vascular occlusions[J]. Lancet, 2020, 396(10266): 1927-1940. DOI: 10.1016/S0140-6736(20)31559-2.
|
10. |
Lau JT, Lee V, Fan D, et al. Knowledge about cataract, glaucoma, and age related macular degeneration in the Hong Kong Chinese population[J]. Br J Ophthalmol, 2002, 86(10): 1080-1084. DOI: 10.1136/bjo.86.10.1080.
|
11. |
Zhang CX, Zhang GM, Ma N, et al. Awareness of age-related macular degeneration and its risk factors among Beijing residents in China[J]. Chin Med J (Engl), 2017, 130(2): 155-159. DOI: 10.4103/0366-6999.197994.
|
12. |
周芬, 謝紅莉, 瞿佳. 眼科資源現狀及服務能力調查[J]. 中國醫院, 2008, 12(4): 14-16. DOI: 10.3969/j.issn.1671-0592.2008.04.006.Zhou F, Xie HL, Qu J. Investigation on ophthalmology resource and service skill[J]. Chinese Hospitals, 2008, 12(4): 14-16. DOI: 10.3969/j.issn.1671-0592.2008.04.006.
|
13. |
Polack S, Yorston D, López-Ramos A, et al. Rapid assessment of avoidable blindness and diabetic retinopathy in Chiapas, Mexico[J]. Ophthalmology, 2012, 119(5): 1033-1040. DOI: 10.1016/j.ophtha.2011.11.002.
|
14. |
鄒海東, 張晳, 許迅, 等. 上海市靜安區曹家渡街道年齡相關性黃斑變性的患病率調查[J]. 中華眼科雜志, 2005, 41(1): 15-19. DOI: 10.3760/j:issn:0412-4081.2005.01.005.Zou HD, Zhang X, Xu X, et al. Prevalence study of age-related macular degeneration in Caojiadu blocks, Shanghai[J]. Chin J Ophthalmol, 2005, 41(1): 15-19. DOI: 10.3760/j:issn:0412-4081.2005.01.005.
|
15. |
Gonder JR, Walker VM, Barbeau M, et al. Costs and quality of life in diabetic macular edema: Canadian burden of diabetic macular edema observational study (C-REALITY)[J/OL]. J Ophthalmol, 2014, 2014: 939315[2014-03-26]. https://pubmed.ncbi.nlm.nih.gov/24795818/. DOI: 10.1155/2014/939315.
|
16. |
單侯乾, 潘蓓, 左麗倩, 等. 蘭州市糖尿病視網膜病變患者住院費用分析[J]. 中國初級衛生保健, 2019, 33(7): 51-54. DOI: 10.3969/j.issn.1001-568X.2019.07.0017.Shan HQ, Pan B, Zou LQ, et al. Analysis on the hospitalization expenses of patients with diabetic retinopathy in Lanzhou[J]. Chinese Primary Health Care, 2019, 33(7): 51-54. DOI: 10.3969/j.issn.1001-568X.2019.07.0017.
|
17. |
Rees G, Xie J, Fenwick EK, et al. Association between diabetes-related eye complications and symptoms of anxiety and depression[J]. JAMA Ophthalmol, 2016, 134(9): 1007-1014. DOI: 10.1001/jamaophthalmol.2016.2213.
|
18. |
陳有信. 對年齡相關性黃斑變性的公眾認知度亟待提高[J]. 中華眼科雜志, 2009, 45(5): 389-392. DOI: 10.3760/cma.j.issn.0412-4081.2009.05.002.Chen YX. Urgent action needed to raise public awareness of age-related macular degeneration in China[J]. Chin J Ophthalmol, 2009, 45(5): 389-392. DOI: 10.3760/cma.j.issn.0412-4081.2009.05.002.
|
19. |
Meads C, Hyde C. What is the cost of blindness?[J]. Br J Ophthalmol, 2003, 87(10): 1201-1204. DOI: 10.1136/bjo.87.10.1201.
|
20. |
Holz FG, Minnella AM, Tuli R, et al. Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: real-world outcomes from the LUMINOUS study[J/OL]. PLoS One, 2020, 15(12): e0244183[2020-12-30]. https://pubmed.ncbi.nlm.nih.gov/33378369/. DOI: 10.1371/journal.pone.0244183.
|
21. |
García Layana A, Adán A, Ascaso FJ, et al. Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: expert recommendations using a Delphi approach[J]. Eur J Ophthalmol, 2020, 30(5): 1042-1052. DOI: 10.1177/1120672 119861623.
|
22. |
Kodjikian L, Baillif S, Couturier A, et al. Recommendations for the management of diabetic macular oedema with intravitreal dexamethasone implant: a national Delphi consensus study[J]. Eur J Ophthalmol, 2022, 32(5): 2845-2856. DOI: 10.1177/11206721 211052852.
|
23. |
?zen S, Sag E, Ben-Chetrit E, et al. Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach[J]. Rheumatology (Oxford), 2021, 60(8): 3799-3808. DOI: 10.1093/rheumatology/keaa863.
|
24. |
陶洋旭, 李建軍. 醫療共識制訂方法: 德爾菲法和名義小組法[J]. 國際眼科縱覽, 2021, 45(5): 369-373. DOI: 10.3760/cma.j.issn.1673-5803.2021.05.001.Tao YX, Li JJ. Delphi method and nominal group method for medical consensus formation[J]. Int Rev Ophthalmol, 2021, 45(5): 369-373. DOI: 10.3760/cma.j.issn.1673-5803.2021.05.001.
|
25. |
Wagner EH. Organizing care for patients with chronic illness revisited[J]. Milbank Q, 2019, 97(3): 659-664. DOI: 10.1111/1468-0009.12416.
|
26. |
曾志童, 王朝昕, 王慧, 等. 基于國內外最新指南的慢性病個體化、精細化健康管理服務分析及我國發展前景——以糖尿病為例[J]. 中國全科醫學, 2021, 24(9): 1037-1044. DOI: 10.12114/j.issn.1007-9572.2021.00.158.Zeng ZT, Wang ZX, Wang H, et al. Individualized and precision health management for diabetes: evidence from the latest guidelines and development prospects in China[J]. Chinese General Practice, 2021, 24(9): 1037-1044. DOI: 10.12114/j.issn.1007-9572.2021.00.158.
|
27. |
薛金玉, 蔣萍萍, 鄭廣勇, 等. 健康教育對社區高血壓患者生存質量的影響[J]. 中華老年心腦血管病雜志, 2015, 17(10): 1048-1051. DOI: 10.3969/j.issn.1009-0126.2015.10.011.Xue JY, Jiang PP, Zheng GY, et al. Influence of health education on quality of life in community hypertensive patients[J]. Chin J Geriatr Heart Brain Vessel Dis, 2015, 17(10): 1048-1051. DOI: 10.3969/j.issn.1009-0126.2015.10.011.
|
28. |
孫曉紅, 劉珂珂, 江華, 等. 慢性病保健模型在糖尿病長期管理中的應用研究[J]. 中國全科醫學, 2018, 21(31): 3878-3881. DOI: 10.12114/j.issn.1007-9572.2018.00.043.Sun XH, Liu KK, Jiang H, et al. Chronic care model in long-term management of diabetes[J]. Chinese General Practice, 2018, 21(31): 3878-3881. DOI: 10.12114/j.issn.1007-9572.2018.00.043.
|
29. |
歐陽玲, 李寶琪, 楊輝. 瓦格納慢性病服務模型在中澳糖尿病管理中的運用[J]. 中國全科醫學, 2020, 23(33): 4236-4240. DOI: 10.12114/j.issn.1007-9572.2020.00.443.Ouyang L, Li BQ, Yang H. Applying the wagner chronic care model in diabetes management: Australian experience and implications to China[J]. Chinese General Practice, 2020, 23(33): 4236-4240. DOI: 10.12114/j.issn.1007-9572.2020.00.443.
|
30. |
Kong JX, Zhu L, Wang HM, et al. Effectiveness of the chronic care model in type 2 diabetes management in a community health service center in China: a group randomized experimental study[J/OL]. J Diabetes Res, 2019, 2019: 6516581[2019-01-03]. https://pubmed.ncbi.nlm.nih.gov/30719455/. DOI: 10.1155/2019/6516581.
|
31. |
Okada M, Wong TY, Mitchell P, et al. Defining nonadherence and nonpersistence to anti-vascularendothelial growth factor therapies in neovascular age-related macular degeneration[J]. JAMA Ophthalmol, 2021, 139(7): 769-776. DOI: 10.1001/jamaophthalmol.2021.1660.
|
32. |
Droege KM, Muether PS, Hermann MM, et al. Adherence to Ranibizumab treatment for neovascular age-related macular degeneration in real life[J]. Graefe's Arch Clin Exp Ophthalmol, 2013, 251(5): 1281-1284. DOI: 10.1007/s00417-012-2177-3.
|
33. |
中華醫學會眼科學分會眼底病學組, 中國醫師協會眼科醫師分會眼底病學組. 中國年齡相關性黃斑變性臨床診療指南(2023年)[J]. 中華眼科雜志, 2023, 59(5): 347-366. DOI: 10.3760/cma.j.cn112142-20221222-00649.Chinese Vitreo-Retina Society of Chinese Medical Association, Fundus Disease Group of Chinese Ophthalmologist Association. Evidence-based guidelines for diagnosis and treatment of age-related macular degeneration in China (2023)[J]. Chin J Ophthalmol, 2023, 59(5): 347-366. DOI: 10.3760/cma.j.cn112142-20221222-00649.
|
34. |
中華醫學會眼科學分會眼底病學組, 中國醫師協會眼科醫師分會眼底病學組. 我國糖尿病視網膜病變臨床診療指南(2022年)——基于循證醫學修訂[J]. 中華眼底病雜志, 2023, 39(2): 99-124. DOI: 10.3760/cma.j.cn511434-20230110-00018.Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association. Evidence-based guidelines for diagnosis and treatment of diabetic retinopathy in China (2022)[J]. Chin J Ocul Fundus Dis, 2023, 39(2): 99-124. DOI: 10.3760/cma.j.cn511434-20230110-00018.
|
35. |
中華醫學會眼科學分會眼底病學組, 中國醫師協會眼科醫師分會眼底病專業委員會. 中國視網膜靜脈阻塞臨床診療路徑專家共識[J]. 中華眼底病雜志, 2024, 40(3): 175-185. DOI: 10.3760/cma.j.cn511434-20240201-00056.Fundus Diseases Group in Ophthalmology Branch of Chinese Medical Association, Professional Committee of Fundus Diseases in Ophthalmology Branch of Chinese Medical Doctor Association. Expert consensus on clinical diagnosis and treatment path of retinal vein occlusion in China[J]. Chin J Ocul Fundus Dis, 2024, 40(3): 175-185. DOI: 10.3760/cma.j.cn511434-20240201-00056.
|
36. |
Flaxel CJ, Adelman RA, Bailey ST, et al. Retinal vein occlusions preferred practice pattern?[J]. Ophthalmology, 2020, 127(2): 288-320. DOI: 10.1016/j.ophtha.2019.09.029.
|
37. |
Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, et al. Guidelines for the management of retinal vein occlusion by the European society of retina specialists (EURETINA)[J]. Ophthalmologica, 2019, 242(3): 123-162. DOI: 10.1159/000502041.
|
38. |
陳玲玲, 仇永貴, 楊順舟. 門診慢病管理的難點與對策探討[J]. 中國醫療管理科學, 2017, 7(2): 45-48. DOI: 10.3969/j.issn.2095-7432.2017.02.011.Chen LL, Qiu YG, Yang SZ. Dififculties of chronic disease management in outpatient clinic and discussion on countermeasures[J]. Chinese Journal of Medical Management Sciences, 2017, 7(2): 45-48. DOI: 10.3969/j.issn.2095-7432.2017.02.011.
|
39. |
羅小蓉. 構建慢性病遠程健康管理模式的探索[J]. 現代醫院管理, 2014, 12(4): 44-46. DOI: 10.3969/j.issn.1672-4232.2014.04.013.Luo XR. Exploration of constructing chronic disease remote health management model[J]. Modern Hospital Management, 2014, 12(4): 44-46. DOI: 10.3969/j.issn.1672-4232.2014.04.013.
|
40. |
Sharma A, Harrington RA, McClellan MB, et al. Using digital health technology to better generate evidence and deliver evidence-based care[J]. J Am Coll Cardiol, 2018, 71(23): 2680-2690. DOI: 10.1016/j.jacc.2018.03.523.
|
41. |
蔡素娟, Bakerjian D. 移動醫療在慢性病管理中的應用研究進展[J]. 中華護理教育, 2016, 13(8): 581-586. DOI: 10.3761/j.issn.1672-9234.2016.08.005.Cai SJ, Bakerjian D. Application research progress of mobile health care in chronic disease management[J]. Chin J Nurs Educ, 2016, 13(8): 581-586. DOI: 10.3761/j.issn.1672-9234.2016.08.005.
|